A61K 9 - Medicinal preparations characterised by special physical form

Patents for A61K 9 - Medicinal preparations characterised by special physical form (299,044)
03/2009
03/18/2009	CN100469374C Method for preparing cough-relieving apophlegmatic Mogolian medicine
03/18/2009	CN100469372C Xindakang drip pill and preparation thereof
03/18/2009	CN100469371C Manufacturing technique for gingko leaf extracts
03/18/2009	CN100469366C Pharmaceutical formulation comprising a proton pump inhibitor and antacids
03/18/2009	CN100469365C Combination of medication for treating colpitis
03/18/2009	CN100469362C Composite amino acid freeze dried powder injection and its preparation process
03/18/2009	CN100469360C Soft capsule of indapamide
03/18/2009	CN100469359C Deer blood powder capsule and preparation process thereof
03/18/2009	CN100469358C Deer heart powder capsule and preparation method thereof
03/18/2009	CN100469357C Tablet for treating difficult menstruation and its preparation
03/18/2009	CN100469356C Slowly released tablet of compound atenolol, and preparation method
03/18/2009	CN100469355C Nutritional supplements and methods of using same
03/18/2009	CN100469354C Acid-gas absorbing tablet and method of use
03/18/2009	CN100469353C Balsalazide sodium enteroclyster and its preparing method
03/18/2009	CN100469339C An exothermic drug plaster
03/18/2009	CA2639640A1 Local vascular delivery of mtor inhibitors in combination with peroxisome proliferators-activated receptor stimulators
03/17/2009	US7504435 Method for stimulating weight loss and/or for lowering triglycerides in patients
03/17/2009	US7504434 3-(acetylamino)-4-{[amino(imino)methyl]amino}-6-carboxy-3,4-dihydro-2H-pyran-2-yl)-dimer; viricide; influenza A or B infection, parainfluenza, mumps or Newcastle disease, myxovirus infections; stability; long time in lungs
03/17/2009	US7504409 Chronic obstructive pulmonary disease; asthma; respiratory system disorders; administering 2-aminonicotinic acid, anthranilic acid, bendroflumethiazide
03/17/2009	US7504386 comprised of benzyl esters of hyaluronic acid and/or internally cross-linked derivatives of hyaluronic acid and may be in the form of gels, membranes, woven tissues or meshes and nonwoven tissues; adhesion prevention
03/17/2009	US7504383 metal at least partially enclosed by a discrete tubular, nanostructure composed of a plurality of aromatic homodipeptides
03/17/2009	US7504363 Methods using four-layer filter for PCR sample preparation
03/17/2009	US7504122 Coated food products containing hydrogenated indigestible starch syrup as a binding agent
03/17/2009	US7504114 Oxybutynin or fentanyl in a nonaqueous liquid having a solubility parameter of 7 to 13 (cal/cm3)1/2 and acetic acid or an acetate (sodium acetate); patches; excellent skin permeability
03/17/2009	US7504090 Hair wax products containing waxes, non-volatile oils and volatile hydrophobic materials
03/17/2009	US7503915 Device for the treatment of a medical fluid
03/17/2009	CA2563972C Delivery system comprising means for controlling internal pressure
03/17/2009	CA2502731C Sustained release composition for oral administration of drugs
03/17/2009	CA2347925C Propofol composition
03/17/2009	CA2319094C Antimicrobial peptides
03/17/2009	CA2309159C Skin penetration enhancing components
03/17/2009	CA2277829C Apparatus and method for coating a material
03/17/2009	CA2262073C Polymeric system for drug delivery and solute separation
03/17/2009	CA2258882C Compositions and methods for altering the biodistribution of biological agents
03/17/2009	CA2192438C Novel composition stimulating the cerebral activity and based on alkaloids having an eburnamenine nucleus, and preparation methods
03/17/2009	CA2171434C Chemically-defined non-polymeric valency platform molecules and conjugates thereof
03/12/2009	WO2009033046A1 Apparatus for delivering treatment to a joint
03/12/2009	WO2009032994A2 Silica-based nanoparticles and methods of stimulating bone formation and suppressing bone resorption through modulation of nf-kb
03/12/2009	WO2009032943A2 Methods and compositions for delivery of growth factor to fibrous connective tissue
03/12/2009	WO2009032907A2 Stay-on selenium foam
03/12/2009	WO2009032870A2 Method to ameliorate oxidative stress and improve working memory via pterostilbene administration
03/12/2009	WO2009032655A1 Method and composition for making an orally disintegrating dosage form
03/12/2009	WO2009032404A1 Controlled surface gelling of mucoadhesive polymers on oral mucosa
03/12/2009	WO2009032380A2 Branched carboxylic acids as fuel lubricity additives
03/12/2009	WO2009032267A2 Contact lens based bioactive agent delivery system
03/12/2009	WO2009032266A2 Dispersions of microparticles and microgels in hydrogels for drug delivery
03/12/2009	WO2009032246A2 Particulate compositions for delivery of poorly soluble drugs
03/12/2009	WO2009032037A1 Controlled release azithromycin solid dosages forms
03/12/2009	WO2009031922A1 Tablet for prophylaxis and treatment of dental and periodontium diseases
03/12/2009	WO2009031919A1 Alcoholism recurrence preventing agent and method for the use thereof
03/12/2009	WO2009031911A1 Cationic liposome carrier for genetic drugs
03/12/2009	WO2009031896A2 Improved liposomes and uses thereof
03/12/2009	WO2009031890A2 A carrier particle for use in bio-applications
03/12/2009	WO2009031859A2 Multi-functional complex for imaging and drug delivery
03/12/2009	WO2009031644A1 Antifungal pharmaceutical composition
03/12/2009	WO2009031642A1 Pharmaceutical composition
03/12/2009	WO2009031620A1 Water-soluble electrospun sheet
03/12/2009	WO2009031577A1 Injection, injection solution and injection kit preparation
03/12/2009	WO2009031575A1 Therapeutic or prophylactic agent for posterior ocular disease comprising lithium salt as active ingredient
03/12/2009	WO2009031318A1 Preparation for external application comprising analgesic/anti-inflammatory agent
03/12/2009	WO2009031006A2 Antiviral topical formulations in the form of a bio-adhesive gel
03/12/2009	WO2009030964A2 Amphiphilic oxalamide organogelators designed for gelation of organic solvents, water and hydrocarbon commercial fuels
03/12/2009	WO2009030666A1 Method of producing a system for delivering active ingredients of plant origin
03/12/2009	WO2009030351A2 Transdermal therapeutic system containing elongate hollow bodies
03/12/2009	WO2009014347A3 Stabilized antioxidant-containing particles, process for preparing the same, and composition comprising the same
03/12/2009	WO2009013435A3 Preservative-free prostaglandin-based ophthalmic solution
03/12/2009	WO2009010842A3 Nanoparticles comprising ionizable, poorly water soluble cellulosic polymers
03/12/2009	WO2009010837A3 Nanoparticles comprising a non-ionizable polymer and an anionic cellulosic polymer
03/12/2009	WO2009007334A3 Transdermal therapeutic systems which contain the substance anastrozole
03/12/2009	WO2009005798A8 Antifungal formulation and method of preparation
03/12/2009	WO2009001043A3 Duloxetine formulation
03/12/2009	WO2009000853A3 Combination formulations comprising darunavir and etravirine
03/12/2009	WO2008157304A3 Stabilized thrombin compositions
03/12/2009	WO2008149230A3 Nanoparticles comprising drug, a non-ionizable cellulosic polymer and tocopheryl polyethylene glycol succinate
03/12/2009	WO2008148798A3 Controlled release pharmaceutical compositions for prolonged effect
03/12/2009	WO2008138085A3 Process for encapsulating chemically active substances and encapsulated product
03/12/2009	WO2008137778A3 Controlled release oral formulations of ion channel modulating compounds and related methods for preventing arrhythmia
03/12/2009	WO2008135855A3 Nanoparticles comprising a cholesteryl ester transfer protein inhibitor and a nonionizable polymer
03/12/2009	WO2008135829A3 Nanoparticles comprising cox-2 inhibitors and a non-ionizable polymer
03/12/2009	WO2008135828A3 Nanoparticles comprising a drug, ethylcellulose, and a bile salt
03/12/2009	WO2008132229A3 Highly concentrated insulin solutions and compositions
03/12/2009	WO2008117018A3 A tablet having improved stability with at least two actives
03/12/2009	WO2008110741A3 Topical pharmaceutical formulation
03/12/2009	WO2008106228A3 Methods and compositions for normalizing meibomian gland secretions
03/12/2009	WO2008094693A3 Compositions for aerosolization of highly conductive solutions
03/12/2009	WO2008092046A3 Amorphous oxcarbazepine and the production thereof
03/12/2009	WO2008067573A3 Drug delivery system
03/12/2009	WO2008055141A3 Liquid formulations of phospholipase enzyme inhibitors
03/12/2009	WO2008041116A3 Formulations of active principles incorporated in slns suitable for transdermal administration
03/12/2009	WO2008013807A9 A novel lactic acid formulation of mk-0457 useful for the treatment of cancer
03/12/2009	WO2005055975A3 Uv-stable semi-solid transdermal systems comprising a photosensitive active ingredient and a uv absorber
03/12/2009	US20090069414 Epicatechin and vasodilation
03/12/2009	US20090069411 Self-emulsifying and self-microemulsifying formulations for the oral administration of taxoids
03/12/2009	US20090069393 Parenteral formulation for epothilone analogs
03/12/2009	US20090069364 Pharmaceutical compositions of 5-alpha-reductase inhibitors and methods of use thereof
03/12/2009	US20090068745 Compositions and methods for performing reverse gene therapy
03/12/2009	US20090068289 Formulation for menopausal women
03/12/2009	US20090068284 administering to the uterine cavity a plurality of physiologically inert beads bearing a tissue necrosing amount of silver nitrate as a solid silver ion source;
03/12/2009	US20090068280 Controlled Release Interferon Drug Products and Treatment of HCV Infections Using Same
03/12/2009	US20090068279 Microspheres with surface projections

1 ... 1095 1096 1097 1098 1099 1100 1101 1102 1103 1104 1105 1106 1107 1108 1109 1110 1111 1112 1113 1114 1115 ... 2991